<DOC>
	<DOCNO>NCT02461589</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate dose-finding semaglutide administer subcutaneously daily versus placebo liraglutide subject type 2 diabetes</brief_summary>
	<brief_title>Dose-finding Semaglutide Administered Subcutaneously Once Daily Versus Placebo Liraglutide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male female , age least 18 year time signing informed consent . Subjects stable diabetes treatment consist diet exercise without metformin ( least 1500 mg daily maximum tolerate dose document patient medical record ) least 90 day prior screen HbA1c ( glycosylated haemoglobin ) : 5386 mmol/mol ( 7.010.0 % ) ( inclusive ) BMI : 25.0 40.0 kg/m^2 ( inclusive ) Simultaneous participation clinical trial investigational medicinal product Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method throughout trial include 7 week followup period ( adequate contraceptive measure require local regulation practice ) . Germany : Only highly effective method birth control accept ( i.e . one result less 1 % per year failure rate use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ) , sexual abstinence vasectomise partner . United Kingdom : Adequate contraceptive measure define establish use oral , injected implant hormonal method contraception , placement intrauterine device intrauterine system , barrier method contraception ( condom occlusive cap spermicidal foam/gel/film/cream/suppository ) , female sterilisation , male sterilisation ( partner sole partner subject ) , true abstinence ( line prefer usual lifestyle ) Treatment medication indication diabetes obesity state inclusion criterion period 90 day screen ( exception shortterm insulin treatment acute illnesses total equal 14 day ) Anticipated initiation change concomitant medication ( 14 consecutive day frequent basis ) know affect weight glucose metabolism ( e.g . orlistat , thyroid hormone , corticosteroid ) History pancreatitis ( acute chronic ) Screening calcitonin equal 50 ng/L Family personal history Multiple Endocrine Neoplasia Type 2 ( MEN2 ) Medullary Thyroid Carcinoma ( MTC ) Severe moderate renal impairment define GFR , estimate 60 ml/min/1.73 m^2 per CKDEPI ( Chronic Kidney Disease Epidemiology ) Within past 180 day screen following : Myocardial infarction , stroke hospitalisation unstable angina and/or transient ischemic attack Currently plan coronary , carotid peripheral artery revascularisation Patients presently classify New York Heart Association ( NYHA ) Class III IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>